ASND•benzinga•
Ascendis Pharma Announces New Data From Week 214 Of Its Phase 2 Path Forward Trial Showing That Long-Term Treatment With TransCon PTH Continued To Provide A Durable Response In Adults With Hypoparathyroidism
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 12, 2025 by benzinga